About Us
Company Leadership
Board of Directors
Investors and Partners
Pipeline
Cefepime-Taniborbactam
Ceftibuten/VNRX-7145
PBP Inhibitor
VNRX-9945
Expanded Access
Publications
Manuscripts
Posters
News & Events
Press Releases
In the News
Events
Careers
Contact
Publications
Publications
Manuscripts
Posters
Cefepime-Taniborbactam
Ceftibuten/VNRX-7145
VNRX-9945
Manuscripts
Click here for Access to the Journal Article
Click here for Access to the Journal Article
>> More Manuscripts
Posters
Discovery and preclinical profile of VNRX-9945, a potent, broadly active core protein inhibitor for the treatment of chronic hepatitis B virus (HBV) infection
Rescue of Ceftibuten Activity by the Oral Beta-Lactamase Inhibitor VNRX-7145 against Enterobacteriaceae Expressing Class A, C and/or D Beta-Lactamases.
Evaluation of the
in vitro
activity of cefepime plus taniborbactam (formerly VNRX-5133) and comparative agents against carbapenem-resistant Enterobacteriaceae.
Oral ceftibuten/VNRX-7145 shows equivalent activity
in vitro
to IV therapeutics against MDR Enterobacteriaceae.
>> More Posters
You are using a browser that is not supported. Please consider changing your browser
